Hi T7
For what its worth I sent an email to PEB in July asking if Midkine would be used in any of PEB's upcoming products and as probably expected the answer was correctly kept under wraps by the commercial director, hopefully and with my limited knowledge it will still form part of the bio-marker make up, answer as replied quoted below
"With regards to other Cxbladder products that may eventuate (for example Triage), the mix of biomarkers will be dictated by the objectives and clinical applications for the product and therefore are part of the product development process. We won’t know the final mix until the end of the development/testing process. Nevertheless MDK continues to be valuable biomarker for Cxbladder"
with Triage about to be launched to market I'm guessing they did know!
Happy Kiwi holding both PEB and CDY for almost 2 years and although it would be nice for the CDY share price to have moved are very happy with the companies building momentum and treasure trove......
- Forums
- ASX - By Stock
- AN1
- Cxbladder royalty (PEB HY result)
Cxbladder royalty (PEB HY result), page-11
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online